These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32478417)

  • 1. The impact of tocilizumab on anxiety and depression in patients with rheumatoid arthritis.
    Tiosano S; Yavne Y; Watad A; Langevitz P; Lidar M; Feld J; Tishler M; Aamar S; Elkayam O; Balbir-Gurman A; Molad Y; Ehrlich S; Abu-Shakra M; Amital D; Amital H
    Eur J Clin Invest; 2020 Sep; 50(9):e13268. PubMed ID: 32478417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responsiveness of the EuroQol EQ-5D and Hospital Anxiety and Depression Scale (HADS) in rheumatoid arthritis patients receiving tocilizumab.
    Traki L; Rostom S; Tahiri L; Bahiri R; Harzy T; Abouqal R; Hajjaj-Hassouni N
    Clin Rheumatol; 2014 Aug; 33(8):1055-60. PubMed ID: 24752345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doppler ultrasound impacts response to intravenous tocilizumab in rheumatoid arthritis patients.
    Morris NT; Brook J; Ben-Artzi A; Martin W; Kermani TA; Avedikian-Tatosyan L; Karpouzas G; Nagam H; Navarro G; Choi S; Taylor MB; Elashoff D; Kaeley GS; Ranganath VK
    Clin Rheumatol; 2021 Dec; 40(12):5055-5065. PubMed ID: 34269927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
    Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the correlation between mood disorder symptoms and disease activity and functional status in rheumatoid arthritis patients.
    Pamukcu M; İzci Duran T; Ulusoy H; Altınbaş K
    Turk J Med Sci; 2021 Dec; 51(6):3008-3016. PubMed ID: 34773692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study.
    Gossec L; Steinberg G; Rouanet S; Combe B
    Clin Exp Rheumatol; 2015; 33(5):664-70. PubMed ID: 26344671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Serum Tocilizumab Trough Concentrations with Clinical Disease Activity Index Scores in Adult Patients with Rheumatoid Arthritis.
    Arad U; Elkayam O
    J Rheumatol; 2019 Dec; 46(12):1577-1581. PubMed ID: 31154416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis.
    Reiss WG; Devenport JN; Low JM; Wu G; Sasso EH
    Rheumatol Int; 2016 Feb; 36(2):295-300. PubMed ID: 26026604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment.
    Cacciapaglia F; Anelli MG; Rinaldi A; Fornaro M; Lopalco G; Scioscia C; Lapadula G; Iannone F
    Mediators Inflamm; 2018; 2018():2453265. PubMed ID: 30405318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.
    Kojima T; Yabe Y; Kaneko A; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Asai S; Hirabara S; Asai N; Hirano Y; Hayashi M; Miyake H; Kojima M; Ishiguro N
    Rheumatology (Oxford); 2015 Jan; 54(1):113-20. PubMed ID: 25102861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical effect of tocilizumab on patients with severe active rheumatoid arthritis].
    Xu S; Xie X; Tang M; Chen J; Tian J; Du J; Mao N; Liu Y; Li S; Song M; Gao J; Ling G; Li F
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1174-1177. PubMed ID: 29093249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab.
    Tuckwell K; Gabay C; Sornasse T; Laubender RP; Wang J; Townsend MJ
    Adv Rheumatol; 2019 Dec; 59(1):54. PubMed ID: 31801637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
    Sagawa A
    Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Successful psychopharmacotherapy of anxiety and depressive disorders improve functional limitations in patients with rheumatoid arthritis].
    Abramkin AA; Lisitsyna TA; Veltishchev DY; Seravina OF; Kovalevskaya OB; Glukhova SI; Nasonov EL
    Ter Arkh; 2022 Jun; 94(5):616-621. PubMed ID: 36286959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
    Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T
    Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis.
    Rubbert-Roth A; Aletaha D; Devenport J; Sidiropoulos PN; Luder Y; Edwardes MD; Jacobs JWG
    Rheumatology (Oxford); 2021 Feb; 60(2):682-691. PubMed ID: 32844216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study.
    Tanaka Y; Kameda H; Saito K; Kaneko Y; Tanaka E; Yasuda S; Tamura N; Fujio K; Fujii T; Kojima T; Anzai T; Hamada C; Fujino Y; Matsuda S; Kohsaka H
    Mod Rheumatol; 2021 Jan; 31(1):42-52. PubMed ID: 31903822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.
    Iwamoto N; Fukui S; Umeda M; Nishino A; Nakashima Y; Suzuki T; Horai Y; Nonaka F; Okada A; Koga T; Kawashiri SY; Fujikawa K; Aramaki T; Ichinose K; Hirai Y; Tamai M; Nakamura H; Terada K; Nakashima M; Mizokami A; Origuchi T; Eguchi K; Ueki Y; Kawakami A
    Mod Rheumatol; 2016 Sep; 26(5):662-6. PubMed ID: 26708444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous Tocilizumab Is Effective for Treatment of Elderly-Onset Rheumatoid Arthritis.
    Kondo N; Fujisawa J; Endo N
    Tohoku J Exp Med; 2020 May; 251(1):9-18. PubMed ID: 32404541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.